This comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options – radiological, surgical, pharmaceutical, and emerging/novel therapies – and help you find the best single or combined therapy.

Building on the success of the previous edition, this extremely thorough revision:

• features a new section on Guidelines for Liver Tumors, where you will find specific strategies for treating common liver malignancies; the guidelines were prepared by the Associate Editors and take into account national and international society guidelines

• reflects actual practice by taking a multidisciplinary approach, with contributions from international experts who have extensive experience with this patient population

• achieves comprehensive and balanced coverage by having each chapter reviewed by the Editor, Deputy Editor, two Associate Editors, and at least one external reviewer

• includes 16 new chapters that cover liver anatomy, histologic changes in the liver, epidemiology and natural history of HCC, CCC and colorectal liver metastases, strategies of liver resection, and economic aspects as well as novel therapies
facilitates the kind of daily interaction among hepatologists, hepatic surgeons, medical oncologists, radiotherapists, and interventional radiologists that is essential when treating patients with complex liver malignancies.

In 44 chapters organized into six major sections, the book covers the full range of liver tumors. The perfect blend of evidence and experience, Malignant Liver Tumors: Current and Emerging Therapies, 3rd Edition, illuminates the path to better patient care.

ABOUT THE AUTHOR

Editor-in-Chief:
Pierre-Alain Clavien
Department of Visceral and Transplant Surgery, University Hospital Zurich, Switzerland

Associate Editors:
Tadatoshi Takayama, Second Department of Surgery, Faculty of Medicine, University of Tokyo, Japan
CM Lo, Liver Transplant Centre, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong
R. Chari, Associate Professor of Surgery and Cancer Biology, Division Chief of Hepatobiliary Surgery and Liver Transplantation, Staff Surgeon, Veterans Affairs Medical Center, Vanderbilt University Medical Center, Nashville, USA
M. Morse, Associate Professor, Duke University Medical School, Durham, USA
J. Llovet, Barcelona-Clinic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomédiques August Pi I Sunyer, Hospital Clínic, University of Barcelona, Catalonia, Spain

For additional product details, please visit https://www.wiley.com/en-us